Sweets maker Imuraya Group Co. sold a record 290 million units of its Azuki Bar ice lolly series to help push its sales to 42.1 billion yen and increase its net profit by 4.7 times from last year to 650 million yen in the fiscal year ending in March 2021.
The stay-at-home trend due to the pandemic buoyed the company's sales of ice lollies.
The Tsu, Mie Prefecture-based firm also sells "yokan” jelly, “shiruko” soup, frozen meat buns, and a new bun product of soybeans instead of pork that have proved popular.
Price drops also helped boost Imuraya’s profits.
However, Imuraya's sales of “nikuman” or buns filled with meat and “anman” or bean paste-filled buns were sluggish.
Imuraya is looking to post sales of 41 billion yen and an 820 million yen net profit in fiscal 2021 ending in March 2022.
Based on its 3-wear midterm management plan through fiscal 2023, Imuraya anticipates sales of 46.5 billion yen and an increase in its overseas business ratio to 7.5 percent from 5.4 percent in fiscal 2020.
Imuraya is seeking to bolster sales of frozen sweets in Southeast Asia, primarily in Malaysia, where it has an affiliate corporation.


Asian Markets Mixed as Fed Decision, Iran Tensions, and Inflation Data Weigh on Sentiment
Oil Prices Slip Amid UAE’s OPEC Exit and Ongoing Iran Conflict Concerns
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement
Asian Stocks Mixed as BOJ Holds Rates, Oil Prices and Fed Outlook Weigh on Markets
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns
U.S. Stock Futures Edge Higher Ahead of Big Tech Earnings and Fed Decision
Trump Signals Prolonged Blockade Strategy Against Iran Amid Rising Tensions
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S.
Gold Prices Dip Ahead of Fed Decision Amid Rising Middle East Tensions
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
US Sanctions Target Iran’s Shadow Banking Network and Terror Financing
European Stocks Slip as U.S.-Iran Tensions and Earnings Season Weigh on Markets
Trump Urges Iran to Sign Nuclear Deal Amid Ongoing Conflict and Port Blockade 



